Obvious effects can be seen after several courses of treatment with gosatuzumab (Todavi)

Gosatuzumab (English name: Trodelvy, trade name: Trodelvy) is an antibody-drug conjugate (ADC), mainly suitable for the treatment of recurrent or metastatic triple-negative breast cancer (TNBC) and some advanced solid tumors that express Trop-2. It combines targeted antibodies and cytotoxic drugs to deliver chemotherapy drugs directly into cancer cells by specifically targeting Trop-2 antigen-expressing cells. It is an emerging method for the current treatment of advanced breast cancer. One of the biggest concerns for patients is that visible results can be seen after just a few courses of treatment.

According to existing clinical research data, most patients begin to show signs of lesion shrinkage, tumor marker decline, or symptom improvement after 2 to 3 courses of treatment (i.e., 4 to 6 weeks) with gosatuzumab. Treatment response varies from person to person. Some patients who are sensitive to drugs may have an initial response after the first course of treatment, while some patients whose disease progresses quickly or has strong drug resistance may need a longer period of time to observe the efficacy.

The efficacy of gosatuzumab is usually evaluated through imaging (such as CT, MRI), and combined with clinical manifestations for comprehensive judgment. If there is still no significant improvement or progression after 3 cycles, the doctor will consider whether to adjust the treatment plan. Some patients will experience side effects (such as leukopenia, diarrhea, nausea, etc.) during treatment. If controlled properly, it will not affect the efficacy, but close observation is required.

In general, gosatuzumab, as a new ADC therapy for advanced breast cancer, has shown superior objective response rate (ORR) and progression-free survival (PFS) in multiple clinical trials. About one-third of patients can achieve a relatively obvious response. In order to obtain the best curative effect, patients should take medication regularly according to the course of treatment, undergo regular check-ups, and adjust the dosage or treatment plan according to the doctor's recommendations to ensure both curative effect and safety.

Reference materials:https://www.drugs.com